Lung
Latest interviews and perspectives
Most recent
Case Studies in Stage III NSCLC: A Summary of the Presentation by Dr. Nancy Nixon
At the 2018 Canadian Lung Cancer Conference (CLCCO), Dr. Nancy Nixon, a medical oncologist at the Tom Baker Cancer Centre in Calgary, discussed two cases of patients with stage III non-small cell lung cancer (NSCLC). Her presentation, summarized in this article,...
Osimertinib: First-line or second-line therapy for EGFR M+ NSCLC? A Summary of the Debate between Dr. Peter Ellis and Dr. Barbara Melosky at CLCCO 2018
At the 2018 Canadian Lung Cancer Conference (CLCCO), Peter Ellis, Medical Oncologist at the Juravinski Hospital and Cancer Centre, Hamilton, ON, and Dr. Barbara Melosky, Medical Oncologist at the British Columbia Cancer Agency, Vancouver, BC, debated whether the...
Are all PD-1 Monoclonal Antibodies Equally Efficacious in Advanced NSCLC? A Summary of the Debate between Dr. Penelope Bradbury and Dr. Paul Wheatley-Price at CLCCO 2018
At the 2018 Canadian Lung Cancer Conference (CLCCO), Dr. Penelope Bradbury, Medical Oncologist at the Princess Margaret Cancer Centre and Mount Sinai Hospital in Toronto, and Dr. Paul Wheatley-Price, Medical Oncologist at the Ottawa Hospital Cancer Centre in Ottawa,...
Lung Cancer Today and Tomorrow: A Canadian Perspective by Dr. Parneet Cheema
At the 2018 Canadian Lung Cancer Conference (CLCCO), Dr. Parneet Cheema, a medical oncologist with the William Osler Health System in Brampton and Toronto, gave a Canadian perspective on recent therapeutic developments in lung cancer. Her presentation, summarized in...
Pembrolizumab as second- or further-line treatment in relapsed malignant pleural mesothelioma: A Swiss registry
Mauti LA, et al. ESMO 2017:1615O Background Programmed death (ligand)-1 (PD-[L]1) checkpoint inhibitors have demonstrated promising activity for patients with malignant pleural mesothelioma (MPM) in early clinical trials,1,2 leading to the off-label use of...
Other
Efficacy and safety of necitumumab and pembrolizumab combination therapy in patients with stage IV NSCLC
Besse B, et al. ESMO 2017:1309P Background Part A (dose-escalating) of an expansion cohort study investigating necitumumab (an epidermal growth factor receptor [EGFR] inhibitor) in combination with a standard dose of pembrolizumab for patients with stage IV non-small...
Osimertinib versus standard of care EGFR TKIs as first-line treatment in patients with EGFR M+ advanced NSCLC: FLAURA
Ramalingam SS, et al. ESMO 2017:LBA2_PR Background Osimertinib, a central nervous system (CNS)-active epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), has shown promising preclinical and early clinical trial data for the first-line treatment of...
Updated results from KEYNOTE-021 cohort G: A randomized phase II study of pemetrexed and carboplatin with or without pembrolizumab as first-line therapy for advanced, non-squamous non-small cell lung cancer
Borghaei H, et al. ESMO 2017:LBA49 Background Previous analyses from cohort G of the phase II KEYNOTE-021 trial have reported significant improvements in overall response rate (ORR) and progression-free survival (PFS) for pembrolizumab plus pemetrexed and carboplatin...
Video: Dr. Mark Vincent discusses the findings of the FLAURA trial presented at ESMO 2017
Video: Dr. Normand Blais discusses the findings of the FLAURA trial presented at ESMO 2017
Video: Dr. Barb Melosky analyzes the findings of the FLAURA trial presented at ESMO 2017
Osimertinib versus standard of care EGFR TKIs as first-line treatment in patients with EGFR M+ advanced NSCLC: FLAURA
Ramalingam SS, et al. ESMO 2017:LBA2_PR Background Osimertinib, a central nervous system (CNS)-active epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI), has shown promising preclinical and early clinical trial data for the first-line treatment of...
PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy in patients with stage III, locally advanced, unresectable NSCLC
Paz-Ares L, et al. ESMO 2017:LBA1_PR Background Most patients with locally advanced, unresectable non-small cell lung cancer (NSCLC) progress after concurrent chemoradiation therapy (cCRT), highlighting a need for novel therapeutic approaches in these patients. At the...
Highlights from the 2017 Canadian Lung Cancer Conference
February 9–10, 2017 Vancouver, BC Introduction As the most commonly diagnosed cancer in Canada, lung cancer is the cause of roughly 25% of cancer-related deaths per year for both men and women.1 Each year in February, Canadian scientists, clinicians, and other...
Overall health status in patients with advanced non-squamous NSCLC treated with nivolumab or docetaxel in CheckMate 057
Reck M, et al. ESMO 2016:1217PD Background In the randomized, open-label, phase III study CheckMate 057, the anti-programmed death-1 antibody nivolumab demonstrated superior overall survival (OS) and a favourable safety profile compared with docetaxel in previously...
Twitter feed